When we analysed the risk of the patients for metachronous metastases within 5 years after diagnosis, we observed a tendency of lower metastasis risk when S100P is low expressed in the tumours (ROC-based cut-off 3.235; Fig. 5a, centre). Here, S100P is linked to neoplasm.